Abstract: Antiatherosclerotic compounds of Formula I are provided: wherein: R is lower alkyl, alkenyl, alkynyl, or —O—(CH2)n—COOR?; R? is lower alkyl; n is an integer of 1–3; Ar is phenyl, or phenyl substituted with one or more of halogen, lower alkyl, alkenyl, alkynyl, alkoxy, perfluoroalkyl, perfluoroalkoxy, or alkylthio; and pharmaceutically acceptable salts thereof.

Abstract: Compounds of Formula I are provided: wherein: R is lower alkyl or branched lower alkyl; and Ar is phenyl, phenyl substituted with one or more of halogen, lower alkyl, lower alkoxy, lower alkylthio, lower alkylamino, cyano, or perfluoroalkoxy, or a heteroaromatic moiety; and pharmaceutically acceptable salts thereof.

Abstract: Compounds of Formula I are provided: 1

Abstract: Antiatherosclerotic compounds of Formula I are provided: 1

Abstract: wherein R is alkyl, alkenyl, or alkynyl; R1 and R2 are each independently hydrogen alkyl, or aryl; and Ar is phenyl, indanyl, benzhydryl, or phenyl, substituted with one or more groups selected from the group consisting of halogen, alkyl, perfluoroalkyl, lower alkoxy, perfluoroalkylalkoxy, dialkylamino, and aroyloxy.

Abstract: Antiatherosclerotic compounds are provided which have the following structure: wherein R is lower alkyl; R1 is hydroxy, amino, or lower alkoxy, R2 and R3 are each independently hydrogen, alkyl or aryl; Ar is phenyl, indanyl, benzhydryl, or phenyl substituted with one or more member selected from the group consisting of halogen, lower alkyl, perfluoroalkyl, lower alkoxy, perfluoroalkylalkoxy, dialkylamino, and aryloxy; or pharmaceutically acceptable salts thereof.

Abstract: Antiatherosclerotic compounds are provided which have the following structure: wherein: R is hydrogen, lower alkyl, alkenyl, alkynyl, aryl, heteroaryl, or aryl or heteroaryl substituted with one or more members of the group consisting of alkyl, hydroxy, alkoxy, perfluoroalkyl, perfluoroalkoxy, alkylthio, nitro, amino, mono or di-alkylamino, and halogen; D is C—H, carbon bound to R5 or nitrogen; R1, R2, R3, and R4 are each independently hydrogen, alkyl, or taken together form a ring; R5 is one or more groups selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, hydroxy, alkoxy, perfluoroalkyl, perfluoroalkoxy, alkylthio, nitro, amino, mono or di-alkylamino, or halogen; n is an integer of 0-3; or pharmaceutically acceptable salts thereof.

Abstract: Disclosed herein are compounds of the formula: wherein R is phenyl or substituted phenyl; or R is furyl, pyridyl or quinolinyl; R1 and R2 are hydrogen, halogen, alkyl, alkoxy, nitro, carboxyl, alkoxy-carbonyl or aryloxycarbonyl; R3 is hydrogen, alkyl, aryl or arylalkyl; R4 and R5 are hydrogen or alkyl; or a pharmaceutically acceptable salt thereof, which are useful as inhibitors of smooth muscle cell proliferation.

Abstract: 1

Abstract: Antiatherosclerotic compounds are provided which have the following structure: 1

Abstract: Antiatherosclerotic compounds are provided which have the following structure: 1

Abstract: Disclosed herein are compounds of formula I or II: wherein R is alkyl phenyl or substituted phenyl; R2 is hydrogen, halogen, alkoxy or alkyl; R1 is hydrogen, alkyl, aryl, arylalkyl, or substituted benzyl; or a pharmaceutically acceptable salt thereof, which are useful as inhibitors of smooth muscle cell proliferation.

Abstract: The compound of formula I: ##STR1## wherein R is phenyl or phenyl optionally substituted with one or more groups selected from halogen, alkyl, perfluoroalkyl, alkoxy, perfluoroalkoxy, hydroxy, alkanoyloxy, aroyloxy or arylalkanoyloxy; R.sup.3 is alkyl, aryl or arylalkyl; or a pharmaceutically acceptable salt thereof, are use for increasing HDL blood levels.

Abstract: The compound of formula I: ##STR1## in which R.sup.1 is alkyl or alkenyl; R.sup.2 is alkyl and R.sup.3 and R.sup.4 are, independently, hydrogen or alkyl; or R.sup.2 is hydrogen and R.sup.3 and R.sup.4 taken together are ortho substituted trimethylene or tetramethylene are useful for increasing blood serum HDL levels.

Abstract: The compound of formula I ##STR1## in which R.sup.1 is alkyl, alkenyl, aryl or arylalkyl; R.sup.2 is alkyl, R.sup.3 is a halogen and R.sup.4 is hydrogen; or R.sup.2 is hydrogen, R.sup.3 is a halogen, and R.sup.4 is alkyl are useful for increasing blood serum HDL levels.

Abstract: This invention relates to the use of 2-thioxotetrahydropyrimidin-4-one derivatives to increase HDL cholesterol concentration and as therapeutic compositions for treating atherosclerotic conditions such as dyslipoproteinemias and coronary heart disease. The compounds of this invention are represented by the formula: ##STR1## wherein: R is C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, or C.sub.2 -C.sub.6 alkynyl; andR.sup.1, R.sup.2, and R.sup.3 are independently hydrogen, halogen or lower alkyl.

Abstract: The compound of formula I ##STR1## in which R.sup.1 is alkyl; and R is alkyl, naphthyl, benzhydryl, fluorophenylmethyl, phenethyl, 1-(fluorophenyl)ethyl, 5-chloro-2-methoxyphenyl, trifluoromethoxyphenyl, trifluoromethylphenyl, methylsulfanylphenyl or pyridyl are useful for increasing blood serum HDL levels.

Abstract: The use of compounds of the formula: ##STR1## where R.sub.1 is alkyl, trifluoromethyl or pyridinyl;R.sub.2 is H, alkyl or substituted arylalkyl, in which the substituents are one or two halogens, carboxyl or alkoxycarbonyl groups;R.sub.3 and R4 are H, alkyl, halogen or nitro;or a pharmaceutically acceptable salt thereof, as inhibitors of smooth muscle cell proliferation.

Abstract: Disclosed herein are compounds of the formula: ##STR1## where Ar.sub.1 and Ar.sub.2 are, independently, pyridinyl, quinolinyl, 1,4-benzodioxanyl, dihydro-1,4-benzodioxanyl, pyrrolyl, azaindolyl or carbazolyl, or a pharmaceutically acceptable salt thereof, which are useful as inhibitors of smooth muscle cell proliferation.

Abstract: Disclosed herein are compounds of the formula: ##STR1## where R.sub.1 is substituted phenyl in which the substituents are one or two halogens, alkyl groups, carboxyl groups or alkoxycarbonyl groups;R.sub.2 is H or alkyl;R.sub.3 and R.sub.4 are, independently, H, alkyl, halogen or nitro;and n is 1, 2 or 3;or a pharmaceutically acceptable salt thereof, which are useful as inhibitors of smooth muscle cell proliferation.